Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gevo

Rigetti Computing

You've probably heard about penny stocks and wondered what why they ignite so much excitement. Investing in stocks that only cost pennies?

Penny Stocks: What They Are & 3 To Watch In The Stock Market Today

BOSTON , Aug. 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a panel discussion titled "Generative AI & Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine" at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.

Ginkgo Bioworks Announces Participation in UBS MedTech, Tools and Genomics Summit 2023

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2023 Earnings Conference Call August 9, 2023 5:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good evening. I am Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2023 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.41 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates

Ginkgo added 21 new Cell Programs to the Foundry platform in Q2 2023 Highlighted continued success selling into large established biotech R&D organizations with recently expanded relationships with Sumitomo, Novo Nordisk, and Merck Ginkgo ended Q2 2023 with approximately $1.1 billion in cash and cash equivalents, providing a strong multi-year runway as Ginkgo continues to drive towards profitability BOSTON , Aug. 9, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2023. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2023 Financial Results

Merck

Shares in Ginkgo Bioworks jumped more than 7% in pre-market trading following the announcement of their collaboration with Merck & Co Inc (NYSE:MRK). The partnership aims to enhance biologics manufacturing.

Ginkgo Bioworks up 7% in pre-market after inking second Merck deal

Ginkgo Bioworks up 6% in pre-market after inking second Merck deal

Ginkgo Bioworks Holdings Inc. shares DNA, were rising more than 5% in Monday's premarket trading after the company said it was collaborating with Merck & Co. Inc. MRK, -0.69% on improvements in biologic manufacturing. Ginkgo plans to use its abilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to boost yields and drive improvements in production efficiency.

Ginkgo Bioworks stock pops as company plans Merck collaboration

BOSTON , Aug. 7, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to improve production efficiency and increase yields.

Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing

Archer Aviation

Codexis

908 Devices

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Cathie Wood's ARK Funds Continue to Buy These 5 Stellar ‘Strong Buy' Stocks Trading Under $10

Teradyne

Twilio

The renowned investor and founder of Ark Invest, Cathie Wood, has set her sights on three disruptive growth stocks that may soon redefine their respective industries. The first stock is a semiconductor company with a promising future amid industry challenges.

3 Growth Stocks Cathie Wood Is Betting On Now: August 2023

BOSTON and PANAMA CITY, Panama, Aug. 3, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it builds Panama's foundational bioeconomy that will serve not only the country, but also the surrounding region.

Ginkgo Bioworks and the Government of the Republic of Panama Announce Plans to Establish New Biosecurity Capabilities

Presentation and Q&A session scheduled for post-market on Wednesday, August 9, 2023 BOSTON , Aug. 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Second Quarter 2023 Results Presentation

Prime Medicine Inc

Cathie Wood has positions in several leading genomic medicine companies. Prime Medicine and Ginkgo Bioworks could be two of her fund's biggest winners in the years to come.

2 Cathie Wood Stocks That Could Be Hidden Gems

Recursion Pharmaceuticals

Schrodinger 

Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.

3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other

Astra Space

Proterra

Virgin Galactic

TuSimple Holdings

Picture this: you're sat with a pile of ‘pennies' in your hand, and you're daydreaming about turning those pennies into dollars. Not in the usual sense, though, you're thinking about penny stocks.

5 Penny Stocks To Watch Under $5 This Week

Viridian Therapeutics

Viridian has a treatment for thyroid eye disease in the works that could be a potential blockbuster. Ginkgo Bioworks programs cells and has huge opportunities in many different industries.

2 Growth Stocks Wall Street Analysts Think Can Double in Value

Ginkgo Bioworks (NYSE: DNA ) stock is rising higher on Wednesday after the company won a contract from the Defense Advanced Research Projects Agency (DARPA). This contract is worth $18 million over a four-year period and has Ginkgo Bioworks joining DARPA's Reimagining Protein Manufacturing ( RPM ) project.

DNA Stock Alert: The $18 Milion Reason Ginkgo Bioworks Is Up Today

ARLINGTON, Va. and BOSTON , July 19, 2023 /PRNewswire/ -- Approved for Public Release, Distribution Unlimited — The Defense Advanced Research Projects Agency ( DARPA ) announced that Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a 4-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Ginkgo Bioworks Awarded DARPA Contract to Reimagine the Manufacturing of Complex Therapeutic Proteins

TOKYO and BOSTON , July 18, 2023 /PRNewswire/ -- Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership. Sumitomo Chemical and Ginkgo Bioworks have been collaborating since 2021 using Ginkgo's synthetic biology platform for the production of products in industries ranging from personal care and cosmetics, to agriculture and pharma.

Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology

BOSTON and GABORONE, Botswana , July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2. Through this program, Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, will collaborate with the MoH to monitor wastewater and nasal swab samples collected on a voluntary, anonymous basis from arriving international travelers for SARS-CoV-2 surveillance.

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry

CRISPR Therapeutics

PagerDuty

Cathie Wood recently added more than a million shares of a synthetic biology company called Ginkgo Bioworks to the Ark Innovation ETF. PagerDuty's automated tech-support platform is a hit with big enterprise customers from tech and non-tech industries.

Cathie Wood Is Buying These 3 Growth Stocks Hand Over Fist. Should You?

Applied DNA Sciences

Dragonfly Energy Holdings Corp

Knightscope

Something that has become one of the go-tos for traders is stock market news. That goes for anything from penny stocks to mega-caps like Apple or Tesla.

Best Penny Stocks to Buy? 5 To Watch With Big News

MannKind

Cassava Sciences Inc

The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the sector.

Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now

BOSTON , July 13, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has been awarded a research contract from the Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence Community, for the Biointelligence and Biosecurity for the Intelligence Community (B24IC) program. Through this program, Ginkgo aims to develop a biosensor that records time-ordered cellular memory for improved traceability and biosecurity.

News for Ginkgo Bioworks Holdings Stock (DNA)